CPDC Celebrates Founder John Valliant and His Sixteen-Year Commitment to CPDC
HAMILTON, ON, July 29, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in radiopharmaceutical development and commercialization, today announced that its Founder, John Valliant, Ph.D., has stepped down from its Board of Directors.
Dr. Valliant established CPDC in 2008 as a Centre of Excellence for the Commercialization of Research in Canada. Under his leadership, CPDC quickly emerged as a leader in nuclear medicine discovery, development, commercialization and distribution.
Dr. Valliant served as CEO of CPDC for eight years before transitioning to the role of CEO at Fusion Pharmaceuticals, a CPDC spin-off company focused on developing next generation radioconjugates. Over the following eight years, John continued his invaluable contributions to CPDC as a Director on the CPDC Board. Fusion Pharmaceuticals was recently acquired by AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led, patient-focused biopharmaceutical company, that develops innovative medicines for millions of patients worldwide.
“It has been an incredible journey and a privilege to have been a part of envisioning, launching and leading CPDC and now watching it continue to be an incredibly successful Centre of Excellence for Commercialization and Research focused on radiopharmaceuticals.” said Dr. Valliant. “I am immensely proud of what we have achieved together and am grateful for the support and dedication of CPDC’s talented leaders, team members, partners and board over the past sixteen years. While I am stepping down from the CPDC Board, I am confident that CPDC will continue to thrive under the leadership of Owen Roberts. I want to extend my deepest appreciation to everyone who has been part of this remarkable journey.”
“We wish John continued success and are excited to see the future impact of his contributions to the field of nuclear medicine,” said Owen Roberts, CEO of CPDC. “As the Canadian and global radiopharmaceutical industry continues to flourish, CPDC remains committed to building on the strong foundation established by John and we extend our deepest gratitude to him for his unwavering dedication and visionary leadership for CPDC over the past sixteen years.”
About CPDC
CPDC is a not-for-profit corporation founded in 2008, with the mission is to improve the quality of Canadian patients’ lives through the commercialization of advanced research and the clinical development of nuclear medicine. In the past 16 years, CPDC has created four Canadian commercial entities that have advanced the availability of radiopharmaceuticals to the Canadian medical community. CPDC’s self-funding business model will continue to identify and advance critical radiopharmaceuticals to meet the needs of Canadian patients and physicians through collaboration with partners including industry, academia, and government. For more information on CPDC, visit www.cpdc.ca and follow on LinkedIn.
Contact:
Owen Roberts, CEO, CPDC: owen@cpdc.ca
